| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Target is the lysine-binding site of plasminogen and plasmin; 6-aminocaproic acid competitively binds lysine residues on plasminogen, preventing plasminogen activation and plasmin-mediated fibrin degradation, thereby inhibiting fibrinolysis; it also serves as a hydrophobic linker to improve near-infrared fluorescence imaging and photothermal cancer therapy.
|
|---|---|
| ln Vitro |
6-Aminocaproic acid hydrochloride (20-180 μg/mL) decreases fibrinolysis in Asian elephant plasma at a 61.5 μg/mL effective concentration [2]. 6-Aminocaproic acid hydrochloride can be employed as a hydrophobic linker to enhance photothermal cancer therapy of PEGylated indocyanine green and near-infrared fluorescence imaging [4].
In vitro, 6-aminocaproic acid hydrochloride (20–180 μg/mL) inhibits fibrinolysis in plasma of Asian elephants, with an effective concentration of 61.5 μg/mL; its antifibrinolytic potency is approximately one-fifth to one-tenth that of tranexamic acid, and it has a shorter half-life, requiring more frequent dosing. |
| ln Vivo |
6-Aminocaproic acid hydrochloride (20-100 mg/kg; single oral dosage) reduces fibrinolysis at all levels studied in dogs [3]. 6-Aminocaproic acid hydrochloride (20-100 mg/kg; single oral dose) is rapidly absorbed (Tmax=1 hour) and promptly excreted in dogs [3].
In dogs, 6-aminocaproic acid hydrochloride (20–100 mg/kg, single oral dose) inhibits fibrinolysis at all doses tested, is rapidly absorbed (Tmax ≈ 1 h), and is rapidly eliminated; in vivo, it also affects intrarenal hemodynamics when administered with tPA, and it has been used as a hydrophobic linker in PEGylated indocyanine green nanoparticles for cancer imaging and photothermal therapy. |
| Enzyme Assay |
Plasminogen or plasmin is incubated with a fluorogenic or chromogenic substrate in the presence of fibrin or a fibrin-like surface and graded 6-aminocaproic acid concentrations; plasmin activity is measured by substrate cleavage, and IC50 values are calculated; binding to plasminogen is assessed by a lysine-binding site assay using a fluorescent lysine analogue or by surface plasmon resonance.
|
| Cell Assay |
Plasma or cell-culture media are incubated with 6-aminocaproic acid hydrochloride (20–180 μg/mL) and a fibrin clot or fluorogenic plasmin substrate; fibrinolysis is measured by clot lysis time or fluorescence, and cell-based assays assess effects on plasminogen activation, cell migration, and viability; imaging studies use 6-aminocaproic acid as a linker in nanoparticle formulations.
|
| Animal Protocol |
Dogs receive 6-aminocaproic acid hydrochloride (20–100 mg/kg, single oral dose), and plasma is collected at serial time points for pharmacokinetic analysis and ex vivo fibrinolysis assays; rats or mice receive 6-aminocaproic acid-containing nanoparticles for imaging or photothermal therapy, and tumor accumulation and therapeutic efficacy are assessed by fluorescence imaging and tumor volume measurements.
|
| References |
| Molecular Formula |
C6H13NO2.HCL
|
|---|---|
| Exact Mass |
167.071
|
| CAS # |
4321-58-8
|
| Related CAS # |
6-Aminocaproic acid;60-32-2
|
| PubChem CID |
12205345
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.092
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
10
|
| Complexity |
83.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCC(=O)O)CCN.Cl
|
| InChi Key |
AENOKLOQCCSDAZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13NO2.ClH/c7-5-3-1-2-4-6(8)9;/h1-5,7H2,(H,8,9);1H
|
| Chemical Name |
6-aminohexanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
